UFM1

Ubiquitin-fold modifier 1 · P61960 · UFM1 on Sugi Atlas →

0 patent compounds predicted against UFM1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to UFM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) PHASE2RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS) PHASE1RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
A Natural History Study of Angelman Syndrome nanRECRUITING
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 nanNOT_YET_RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Using Mobile Technology to Improve Self-Regulation nanCOMPLETED
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Genetic Analysis to Predict the Development of Paget's Disease nanACTIVE_NOT_RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
Stakeholders of Rare Diseases Informing Values In Neuroethics nanRECRUITING
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UFM1 binder may also engage these)

ProteinNameSimilarity
P61961 1.000 P61961 →
Q5R4N5 1.000 Q5R4N5 →
Q5BJP3 1.000 Q5BJP3 →
B3DL37 1.000 B3DL37 →
C1BJ98 1.000 C1BJ98 →
Q2KJG2 1.000 Q2KJG2 →
Q5ZMK7 1.000 Q5ZMK7 →
Q09JK2 1.000 Q09JK2 →
Q176V0 1.000 Q176V0 →
B5E0K3 1.000 B5E0K3 →
B5LVL2 1.000 B5LVL2 →
B0WK43 1.000 B0WK43 →
B4LP65 1.000 B4LP65 →
A8DYH2 1.000 A8DYH2 →
Q61E22 1.000 Q61E22 →
B0G186 1.000 B0G186 →
B4GBR1 1.000 B4GBR1 →
Q4R4I2 1.000 Q4R4I2 →
B4JVK9 1.000 B4JVK9 →
Q5PU89 1.000 Q5PU89 →
Q94EY2 0.999 Q94EY2 →
Q4N927 0.999 Q4N927 →
A8Q8M5 0.999 A8Q8M5 →
B4KSR4 0.999 B4KSR4 →
Q803Y4 0.998 Q803Y4 →
Q5RJW4 0.995 Q5RJW4 →
Q7PXE2 0.995 Q7PXE2 →
A8D888 0.995 A8D888 →
B9ENM6 0.995 B9ENM6 →
Q9CA23 0.994 Q9CA23 →